Article

Specialized role of migratory dendritic cells in peripheral tolerance induction

The Journal of clinical investigation (Impact Factor: 15.39). 01/2013; 123(2). DOI: 10.1172/JCI65260
Source: PubMed

ABSTRACT Harnessing DCs for immunotherapies in vivo requires the elucidation of the physiological role of distinct DC populations. Migratory DCs traffic from peripheral tissues to draining lymph nodes charged with tissue self antigens. We hypothesized that these DC populations have a specialized role in the maintenance of peripheral tolerance, specifically, to generate suppressive Foxp3+ Tregs. To examine the differential capacity of migratory DCs versus blood-derived lymphoid-resident DCs for Treg generation in vivo, we targeted a self antigen, myelin oligodendrocyte glycoprotein, using antibodies against cell surface receptors differentially expressed in these DC populations. Using this approach together with mouse models that lack specific DC populations, we found that migratory DCs have a superior ability to generate Tregs in vivo, which in turn drastically improve the outcome of experimental autoimmune encephalomyelitis. These results provide a rationale for the development of novel therapies targeting migratory DCs for the treatment of autoimmune diseases.

0 Bookmarks
 · 
178 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dendritic cells (DC) play a prominent role in the priming of CD8(+) T cells. Vaccination is a promising treatment to boost tumor-specific CD8(+) T cells which is crucially dependent on adequate delivery of the vaccine to DC. Upon subcutaneous (s.c.) injection, only a small fraction of the vaccine is delivered to DC whereas the majority is cleared by the body or engulfed by other immune cells. To overcome this, we studied vaccine delivery to DC via CD40-targeting using a multi-compound particulate vaccine with the aim to induce potent CD8(+) T cell responses. To this end, biodegradable poly(lactic-co-glycolic acid) nanoparticles (NP) were formulated encapsulating a protein Ag, Pam3CSK4 and Poly(I:C) and coated with an agonistic αCD40-mAb (NP-CD40). Targeting NP to CD40 led to very efficient and selective delivery to DC in vivo upon s.c. injection and improved priming of CD8(+) T cells against two independent tumor associated Ag. Therapeutic application of NP-CD40 enhanced tumor control and prolonged survival of tumor-bearing mice. We conclude that CD40-mediated delivery to DC of NP-vaccines, co-encapsulating Ag and adjuvants, efficiently drives specific T cell responses, and therefore, is an attractive method to improve the efficacy of protein based cancer vaccines undergoing clinical testing in the clinic. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Biomaterials 11/2014; DOI:10.1016/j.biomaterials.2014.10.053 · 8.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs in vivo by means of monoclonal antibodies, carbohydrate moieties or viral vectors specific for DC receptors. All these approaches have been shown to (re) activate tumor-specific immune responses in mice, often mediating robust therapeutic effects. In 2010, the first DCbased preparation (sipuleucel-T, also known as Provenge�) has been approved by the US Food and Drug Administration (FDA) for use in humans. Reflecting the central position occupied by DCs in the regulation of immunological tolerance and adaptive immunity, the interest in harnessing them for the development of novel immunotherapeutic anticancer regimens remains high. Here, we summarize recent advances in the preclinical and clinical development of DC-based anticancer therapeutics.
    OncoImmunology 05/2014; 3(11). DOI:10.4161/21624011.2014.963424 · 6.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper analyzes the performance of well known Least-mean-square (LMS) and Recursive-least-squares (RLS) adaptive algorithms in terms of bit error rate (BER) verses signal to noise ratio (SNR) performances on the space-time coded multicarrier CDMA (STC-MC-CDMA) systems in frequency selective environments. For system we consider Alamouti's space-time coding scheme that involves two transmit antennas and provide transmit diversity at transmitting end. We compare the performance of RLS and LMS detector with help of computer simulation. It is found that BER performance of RLS detector is always considerably better than that of LMS detector. Thus, RLS detector outperforms the LMS detector. In this paper, we propose an application of the RLS algorithm for the detection of space-time coded MC-CDMA system. Simulation results presented in this paper confirms the performance analysis.
    2014 International Conference on Communication Systems and Network Technologies (CSNT); 04/2014

Full-text

Download
95 Downloads
Available from
May 23, 2014